Company news

| Updated on January 13, 2018 Published on March 07, 2017

Cadila Healthcare and its US subsidiary Zydus Pharmaceuticals Inc have settled all outstanding litigation related to Trokendi extended release capsules with Supernus Pharmaceuticals Inc. Under the agreement, Supernus has granted Zydus a license to market the latter’s generic of Trokendi XR capsules fromJanuary 1, 2023 or earlier. Topiramate or Trokendi extended release capsules are prescribed to patients who suffer fromepilepsy. Shares of Cadila Healthcare slipped 0.45 per cent at ₹435.70 on the BSE.

Crompton Greaves has completed the sale of its B2B automation business to Saudi Arabia’s Alfanar for an enterprise value of €120 million (about ₹845 crore). The company, along with its subsidiary CG International BV, has completed the sale with effect from March 6, the company said in a notification to the exchanges. In November 2016, the company had announced its decision to sell its automation business to Alfanar. The proceeds of the sale will be used to retire a substantial portion of the company’s international debt. The stock of Crompton Greaves gained 2.9 per cent at ₹70.85 on the BSE.

Brooks Laboratories’ unit-II in Vadodara, Gujarat, started commercial production from Tuesday, the company said in an exchange filing. The unit is a dedicated carbapenem plant that will cater to the regulated markets of the US, Europe, Australia, New Zealand, and South Africa. Shares of the contract manufacturing company jumped 6.21 per cent at ₹146.30 on the BSE.

Published on March 07, 2017
This article is closed for comments.
Please Email the Editor